FDA Regulatory Action: Church & Dwight's Zicam Elderberry Drops Recalled Over Labeling Non-Compliance
Church & Dwight Co., Inc. faces FDA regulatory action, initiating a Class II recall for 21,912 bottles of Zicam Cold Remedy Medicated Fruit Drops - Elderberry due to undeclared elderberry. This significant enforcement highlights critical compliance gaps in OTC drug labeling, posing substantial supply chain and regulatory risks for global chemical and life sciences firms. Procurement and regulatory teams must scrutinize ingredient declarations rigorously.
FDA Mandates Class II Recall for Church & Dwight's Zicam Elderberry Drops
Church & Dwight Co., Inc. has initiated a Class II recall for its ZICAM COLD REMEDY MEDICATED FRUIT DROPS - ELDERBERRY, a significant regulatory action underscoring critical labeling compliance failures. The recall, identified as D-0095-2026 and initiated on October 1, 2025, targets product containing Zinc Acetate Anhydrous, Zinc Gluconate, and Sambucus Nigra Flowering Top. The core violation stems from a labeling mix-up where the product in the bottle contained elderberry, specifically Sambucus Nigra Flowering Top, but the label failed to declare its inclusion as an ingredient. This omission affects 21,912 bottles from Lot#: BE51396303, with an expiration date of May 2027. For procurement directors, this event necessitates immediate review of supplier qualification processes, particularly for over-the-counter (OTC) drug manufacturers, to ensure stringent label verification protocols are in place. Regulatory affairs heads must recognize the heightened scrutiny on ingredient declarations, especially for botanical components, which can carry allergen implications or drug interaction risks, demanding robust internal audit mechanisms to prevent similar non-compliance across their product portfolios.
Commercial Reach and Supply Chain Vulnerabilities Exposed by Zicam Recall
The recall of 21,912 bottles of Zicam Medicated Fruit Drops Elderberry Flavor (NDC 10237-469-25) highlights significant commercial and supply chain vulnerabilities for Church & Dwight Co., Inc. and the broader OTC market. The affected product was distributed nationwide within the United States, indicating a broad market exposure and potentially widespread consumer impact. For supply chain VPs, this incident underscores the critical importance of end-to-end traceability and robust recall logistics capabilities. Managing the reverse logistics for over 21,000 units across a national distribution network presents substantial operational challenges, including inventory write-offs, potential stock-outs at retail points, and the associated financial costs. Business development executives must consider the immediate and long-term reputational damage. Such labeling errors can erode consumer trust, impacting brand loyalty and future market penetration for Zicam and other Church & Dwight products. This event serves as a stark reminder that even seemingly minor labeling discrepancies can trigger extensive and costly commercial disruptions, demanding proactive risk mitigation strategies throughout the product lifecycle.
Navigating Class II Regulatory Action and Voluntary Firm-Initiated Responses
The FDA's classification of this event as a Class II recall signifies that the product's use or exposure may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. While the recall was "Voluntary: Firm initiated" by Church & Dwight Co., Inc., with initial notification via letter, this does not diminish the regulatory gravity. For regulatory affairs heads, this emphasizes the expectation of proactive self-policing and swift action upon identifying non-conformities. The FDA's active oversight is evident through the center classification date of October 22, 2025, and the report date of October 29, 2025, indicating ongoing monitoring of the firm's response. This level of regulatory engagement means that even voluntary actions require comprehensive documentation, root cause analysis, and implementation of corrective and preventive actions (CAPA). Procurement teams must factor in the potential for extended qualification timelines for suppliers undergoing significant regulatory scrutiny, impacting the continuity of supply for critical raw materials or finished products, especially in the competitive OTC cold remedy market.
Proactive Strategies for Mitigating Labeling Compliance Risks in OTC Drugs
The Church & Dwight Zicam recall serves as a critical case study for all global chemical and life sciences companies on the imperative of robust labeling compliance, particularly for multi-ingredient OTC drugs. The failure to declare Sambucus Nigra Flowering Top, a botanical ingredient, alongside Zinc Acetate Anhydrous and Zinc Gluconate, highlights the complexity of managing formulations that combine traditional APIs with natural extracts. For business development executives, this incident underscores the need for thorough due diligence on regulatory pathways and labeling requirements when exploring new product formulations or market entries, especially in regions with stringent allergen or botanical ingredient disclosure laws. Procurement directors should implement enhanced audit protocols for contract manufacturing organizations (CMOs) and raw material suppliers, demanding proof of rigorous label generation, verification, and change control processes. This proactive approach is essential to prevent similar labeling mix-ups, which can lead to costly recalls, significant brand damage, and potential legal liabilities, safeguarding both consumer safety and market position. Recent parallel events, such as Essential Wellness Pharma's sterility failure recall, reinforce the broader industry trend of heightened FDA scrutiny on quality and compliance.
Church & Dwight's Remediation Path and Future Regulatory Scrutiny
With the recall status currently "Ongoing," Church & Dwight Co., Inc. faces a mandatory and detailed remediation process following the labeling non-compliance for Zicam Cold Remedy Medicated Fruit Drops - Elderberry. Regulatory affairs heads at Church & Dwight will be required to conduct a thorough root cause analysis to pinpoint precisely why elderberry was omitted from the label of Lot#: BE51396303, despite its presence in the product. This investigation must extend beyond the immediate error to systemic failures in their quality management system, including label design, approval, printing, and packaging line verification. The FDA will expect a comprehensive corrective and preventive action (CAPA) plan, detailing how the company will prevent recurrence across all relevant product lines. For supply chain VPs, this means anticipating potential delays in future product launches or re-releases from Church & Dwight as these remediation efforts are implemented and verified. The incident will likely result in increased regulatory scrutiny on Church & Dwight's other OTC drug products and manufacturing processes, impacting their operational efficiency and market access for an extended period. This underscores for all industry players the critical importance of investing in robust quality systems to maintain regulatory good standing and avoid protracted enforcement actions.